drugset / Trial / NCT04358432
A Study of PCSK9 Inhibitor AK102 in Patients With Hypercholesterolemia
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a double-blind, randomized, placebo-controlled, multicenter study to evaluate the safety and efficacy of AK102 in patients with Hypercholesterolemia Patients at Very High or High Risk of Cardiovascular Disease . The primary objective of this study is to evaluate the efficacy of AK102 in patients with Hypercholesterolemia Patients at Very High or High Risk of Cardiovascular Disease .
Timeline
- Start
- 2020-05-13
- Primary completion
- 2021-02-25
- Completion
- 2021-02-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AK102 | Monoclonal antibody | 75 mg | Subcutaneous |
| Subject | AK102 | Monoclonal antibody | 150 mg | Subcutaneous |
| Subject | AK102 | Monoclonal antibody | 300 mg | Subcutaneous |
| Subject | AK102 | Monoclonal antibody | 450 mg | Subcutaneous |
| Background | Ezetimibe | Unknown | — | — |